Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-Controlled, Multicentre Study.
Latest Information Update: 28 Oct 2015
Price :
$35 *
At a glance
- Drugs Endostatin (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Shandong Simcere Medgenn Bio-Pharmaceutical
- 02 Sep 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.